Qiagen and Eppendorf form alliance
Qiagen and Eppendorf have announced that they have formed a strategic alliance that includes co-development and co-marketing of complementary and optimised products. The alliance is intended to link the brands and product lines and to ensure the highest compatibility of their products targeting the research, applied testing and molecular diagnostics.
In addition, Qiagen has acquired Eppendorf's reagent business which includes the Eppendorf's Prime nucleic acid sample preparation and PCR reagent product lines and related intellectual property. The acquired assets represent an attractive portfolio of preanalytical and nucleic acid amplification consumables as well as a very promising pipeline of proprietary technologies for nucleic acid handling, separation, purification and amplification.
Through the alliance, Qiagen and Eppendorf intend to focus on improving biological sample management and analysis. The availability of combined and optimised products should create significant benefits for customers in research, applied testing and molecular diagnostics.
Govt and industry fund health and biotech innovation in SEQ
The SEQ Innovation Economy Fund has awarded eight projects $94m in government funding, while...
Does the 2025–26 Budget do enough for science?
AAMRI has described the 2025–26 federal Budget as "very disappointing" for the...
Ming Long appointed Chair of CSIRO
Minister for Industry and Science Ed Husic has announced the appointment of Ming Long to the role...